Leukotrienes in asthma

Advances in Experimental Medicine and Biology

Volumn 525, Issue , 2003, Pages 1-5

  Drazen, Jeffrey M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BECLOMETASONE; BRONCHOCONSTRICTING AGENT; CORTICOSTEROID; HISTAMINE; LEUKOTRIENE; LEUKOTRIENE ANTIBODY; LEUKOTRIENE E4; LIPOXYGENASE INHIBITOR; MONTELUKAST; PEPTIDOLEUKOTRIENE; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHOSPASM; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; FORCED EXPIRATORY VOLUME; HUMAN; LIPOGENESIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; URINARY EXCRETION;

EID: 0037868080     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-9194-2_1     Document Type: Conference Paper

References (28)

1. Drazen JM, Austen KF. Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2alpha on pulmonary mechanics in the guinea pig. J Clin Invest 1974; 53:1679-1685.
2. Brocklehurst WE. The release of histamine and the formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol (Lond) 1960; 151:416-435.
3. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979; 76:4275-4279.
4. Obyrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127(6):472-480.
5. Drazen JM, Israel E, Obyrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340(3):197-206.
6. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323:645-655.
7. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288:484-486.
8. Weiss JW, Drazen JM, Coles N, McFadden ERJ, Weller PF, Corey EJ et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982; 216:196-198.
9. Hammarstrom S, Orning L, Bernstrom K. Metabolism and excretion of cysteinyl-leukotrienes. Adv Prost Thromb Leukot Res 1986; 16:383-396.
10. Taylor GW, Taylor I, Black P, Maltby NH, Turner N, Fuller RW et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1:584-588.
11. Drazen JM, Obrien J, Sparrow D, Weiss ST, Martins MA, Israel E et al. Recovery of Leukotriene-E4 from the Urine of Patients with Airway Obstruction. Am Rev Respir Dis 1992; 146:104-108.
12. 4 and histamine excretion rates in normal subjects and patients with mild-to- moderate asthma. J Allergy Clin Immunol 1995; 96(5 Part 1):643-651.
13. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337:1062-1063.
14. Israel E, Rubin P, Kemp JP, Grossman J, Pierson WE, Siegel SC et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119:1059-1066.
15. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized controlled trial. Ann Int Med 1999; 130:487-495.
16. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Brit Med Bull 2000; 56(4):1054-1070.
17. Awni WM, Locke C, Dube LM, Cavanaugh JH. Evaluation of the diurnal variation in the pharmaeokinetics of zileuton in healthy volunteers. J Clin Pharmacol 1997; 37(5):388-394.
18. Drazen JM, Yandava C, Dube L, Szczerback N, Hippensteel R, Pillari A et al. Pharmaengenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics 1999; 22:170-172.
19. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT1 antagonist, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12:1-6.
20. Bleeeker ER, Welch MJ, Weinstein SF, Kalberg C, Johnson M, Edwards L et al. Low-dose inhaled fiuticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000 Jun; 105 (6 Pt 1):1123-9 2000; 105(6 Pt 1):1123-1129.
21. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Amer J Respir Crit Care Med 1999; 160(6):1862-1868.
22. Yokoyama A, Kohno N, Sakai K, Hirasawa Y, Kondo K, Hiwada K. Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids. J Asthma 1998; 35(1):57-62.
23. Virchow JC, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Amer J Respir Crit Care Med 162[2], 578-585. 2000. Ref Type: Journal (Full)
24. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo- controlled trial. Lancet 2001; 357(9273):2007-2011.
25. Bel EH, Desmet M, Rossing TH, Timmers MC, Dijkman JH, Sterk PJ. The effect of a specific oral PAF-antagonist, MK-287, on antigen- induced early and late asthmatic reactions in man. American Review Respiratory Disease 143, A811. 1991. Ref Type: Abstract
26. Wilkens JH, Wilkens H, Uffmann J, Bovers J, Fabel H, Frolich JC. Effects of a PAF-antagonist (BN 52063) on bronchoconstriction and platelet activation during exercise induced asthma. Br J Clin Pharmacol 1990; 29:85-91.
27. Bryan SA, Oconnor BJ, Matti S, Leckie MJ, Kanabar V, khan j et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsivness, amd the late asthmatic response. Lancet 2000; 356:2149-2153.
28. Leckie MJ, ten Brincke A, khan j, Diamant Z, O'Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000; (In Press).